Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 8INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 767Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 339Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 236Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

Everolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Lymphangioleiomyomatosis × Clear all
NCT03525834 2021-09-09

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Novartis

Phase 4 Completed
40 enrolled 10 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

NCT01059318 2020-11-19

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Novartis

Phase 2 Completed
24 enrolled 13 charts

Lymphangioleiomyomatosis

NCT00790400 2017-02-17

EXIST-2

Novartis

Phase 3 Completed
118 enrolled 15 charts
CNS

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡